Forte Biosciences (FBRX) Misses Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St futures muted as investors monitor US-Iran negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Forte Biosciences, Inc. Announces Third Quarter 2022 Results and Provides Business Update
November 14, 2022 4:01 PM ESTÂ -FB-102 Continues to Advance Towards the Clinic and Holds Significant Market Potential Across a Variety of Indications-
-Leadership Strengthened with the Appointment of Scott Brun, M.D. to the Board of Directors-
-Ended third quarter 2022 with approximately $44.0 million in cash and cash equivalents-
DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc.... More
